RxDoctor Payments Data

Alan Mickish, MD

Family Medicine · Eastland, TXNPI 1215045240

Payments from drug & device makers

$996in general payments, 2019–2025

Across 60 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$270
  • Novartis$86
  • Novo Nordisk$74
  • Amgen$63
  • AbbVie$63
  • Corcept Therapeutics$53
  • plus $386 from 16 others

What the payments were for

  • Food & beverage$996100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$996 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$138,092
Medicare patients
334
Services billed
17,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$143,581
MounjaroTirzepatide117$136,647
EliquisApixaban131$98,760
Tresiba Flextouch U-100Insulin Degludec67$47,078
FarxigaDapagliflozin Propanediol42$41,343
Tresiba Flextouch U-200Insulin Degludec42$38,326
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$36,305
MyrbetriqMirabegron48$31,172
XareltoRivaroxaban62$29,803
Bydureon BciseExenatide Microspheres12$19,208
JardianceEmpagliflozin24$17,722
Xigduo XrDapaglifloz Propaned/Metformin13$12,641
JanumetSitagliptin Phos/Metformin Hcl26$8,570
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$7,533
Combivent RespimatIpratropium/Albuterol Sulfate12$6,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$74$143,581112 claims
Lilly USA, LLCMounjaro$16$136,647117 claims
PfizerEliquis$49$98,760131 claims
AstraZenecaFarxiga$270$41,34342 claims
GSKTrelegy Ellipta, Incruse Ellipta$36$39,91359 claims
Astellas Pharma US IncMyrbetriq$19$31,17248 claims
Johnson & JohnsonXarelto$14$29,80362 claims
Boehringer IngelheimJardiance, Combivent Respimat$15$23,90436 claims
Arbor Pharmaceuticals, Inc.Edarbi$28$5,71020 claims
AbbVieSynthroid$63$3,11860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Eastland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →